NASDAQ · UPC

Universe Pharmaceuticals Inc.

$3.39 -$0.40 (-10.55%) 1D Market open

Key Metrics

$2.46M
Market cap
P/E · TTM
$17.86B
Revenue · TTM
−$3.67B
Net income
EPS · TTM $-607,754.88
Dividend yield
Free cash flow −$5.32B
Beta · 1Y 0.75
EBITDA · TTM −$3.15B
Gross margin 35.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jun 29 high, the share price fell 72%.

    Peak close $12.18 on Jun 29; trough close $3.39 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -72%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 30
    The stock moved -49.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 30
  • Jun 29
    The stock moved +311.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.46M
Enterprise value
Shares outstanding647.8K
52-wk range$2.00 – $17.96
Avg volume · 20D128.4K
Net cash
Book value / share$9,289,889.11
ExchangeNASDAQ
About Universe Pharmaceuticals Inc.
IPO dateMar 23, 2021
Employees216

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their gen…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.00
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 35.3%
Operating -20.6%
Net -20.6%
FCF -29.8%
ROE / ROIC -13.1% · —

Financial Health

Current ratio4.07
Quick ratio3.90
Debt / equity0.04
Debt / EBITDA -0.67
Net cash
Working capital$40.43B

Cash Flow · TTM

Operating CF −$5.05B
Capex −$266.77M
Free cash flow −$5.32B
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2024-03-31 · computed by TickerWolf from SEC filings